(Q36327377)

13 August 2017

1 reference

title

Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides (English)

1 reference

13 August 2017

0 references

Paulo Fontoura

1

1 reference

13 August 2017

Hideki Garren

series ordinal

2

1 reference

13 August 2017

Lawrence Steinman

series ordinal

3

1 reference

13 August 2017

publication date

1 September 2005

1 reference

International Reviews of Immunology

13 August 2017

published in

1 reference

13 August 2017

volume

24

1 reference

13 August 2017

issue

5-6

1 reference

13 August 2017

page(s)

415-446

1 reference

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

The Effects of the Injection of Normal Brain Emulsion into Rabbits, with Special Reference to the Aetiology of the Paralytic Accidents of Antirabic Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

ENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Production of experimental allergic encephalomyelitis in guinea pigs with fractions isolated from bovine spinal cord and killed tubercle bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Allergic encephalomyelitis: Isolation and characterization of encephalitogenic peptides from the basic protein of bovine spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Encephalitogenic protein: structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Allergic encephalomyelitis in monkeys induced by a peptide from the A1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Experimental Allergic Encephalomyelitis: Synthesis of Disease-Inducing Site of the Basic Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Essential chemical requirements for induction of allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Assessment of animal models for MS and demyelinating disease in the design of rational therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

T cells responsive to myelin basic protein in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Oligoclonal bands and antibody responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Identification of autoantibodies associated with myelin damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Future immunotherapies in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Design of effective immunotherapy for human autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Prevention of experimental allergic encephalomyelitis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Acquired resistance to experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Suppression of experimental "allergic" encephalomyelitis in guinea pigs by encephalitogenic proteins extracted from homologous brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Suppression of the Immune Response: Reversal of the Disease State with Antigen in Allergic Encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Current issues in the treatment of human diseases by mucosal tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Protection against experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Immunomodulation by the copolymer glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Degeneracy, as opposed to specificity, in immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

DNA vaccines: immunology, application, and optimization*

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

DNA vaccines: a key for inducing long-term cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Toll meets bacterial CpG-DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Assuring the quality, safety, and efficacy of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

The regulation of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

DNA vaccines against human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

DNA vaccination in the treatment of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFNbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Differential prevention of experimental autoimmune encephalomyelitis with antigen-specific DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Immunotherapy of multiple sclerosis: where are we? Where should we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Various Types of Acquired Resistance to Experimental ‘Allergic’ Encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500379655

10.1080/08830180500379655

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference